Ocaña A - Search Results

1

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

Scaltriti M, Rojo F, Ocaña A, Anido J, Guzman M, Cortes J, Di Cosimo S, Matias-Guiu X, Ramon y Cajal S, Arribas J, Baselga J. Scaltriti M, et al. Among authors: ocana a. J Natl Cancer Inst. 2007 Apr 18;99(8):628-38. doi: 10.1093/jnci/djk134. J Natl Cancer Inst. 2007. PMID: 17440164

2

High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene.

Bruna A, Darken RS, Rojo F, Ocaña A, Peñuelas S, Arias A, Paris R, Tortosa A, Mora J, Baselga J, Seoane J. Bruna A, et al. Among authors: ocana a. Cancer Cell. 2007 Feb;11(2):147-60. doi: 10.1016/j.ccr.2006.11.023. Cancer Cell. 2007. PMID: 17292826 Free article.

3

Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer.

de Alava E, Ocaña A, Abad M, Montero JC, Esparís-Ogando A, Rodríguez CA, Otero AP, Hernández T, Cruz JJ, Pandiella A. de Alava E, et al. Among authors: ocana a. J Clin Oncol. 2007 Jul 1;25(19):2656-63. doi: 10.1200/JCO.2006.08.6850. J Clin Oncol. 2007. PMID: 17602072

4

Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer.

Amir E, Ocaña A, Seruga B, Freedman O, Clemons M. Amir E, et al. Among authors: ocana a. Cancer Treat Rev. 2010 Aug;36(5):410-5. doi: 10.1016/j.ctrv.2009.12.012. Epub 2010 Jan 25. Cancer Treat Rev. 2010. PMID: 20100635 Review.

5

Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.

Seoane S, Montero JC, Ocaña A, Pandiella A. Seoane S, et al. Among authors: ocana a. J Natl Cancer Inst. 2010 Sep 22;102(18):1432-46. doi: 10.1093/jnci/djq315. Epub 2010 Sep 1. J Natl Cancer Inst. 2010. PMID: 20811002 Free article.

6

Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.

Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Amir E, et al. Among authors: ocana a. J Natl Cancer Inst. 2011 Sep 7;103(17):1299-309. doi: 10.1093/jnci/djr242. Epub 2011 Jul 9. J Natl Cancer Inst. 2011. PMID: 21743022 Review.

7

HER3 overexpression and survival in solid tumors: a meta-analysis.

Ocana A, Vera-Badillo F, Seruga B, Templeton A, Pandiella A, Amir E. Ocana A, et al. J Natl Cancer Inst. 2013 Feb 20;105(4):266-73. doi: 10.1093/jnci/djs501. Epub 2012 Dec 8. J Natl Cancer Inst. 2013. PMID: 23221996

8

Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis.

Vera-Badillo FE, Templeton AJ, de Gouveia P, Diaz-Padilla I, Bedard PL, Al-Mubarak M, Seruga B, Tannock IF, Ocana A, Amir E. Vera-Badillo FE, et al. Among authors: ocana a. J Natl Cancer Inst. 2014 Jan;106(1):djt319. doi: 10.1093/jnci/djt319. Epub 2013 Nov 22. J Natl Cancer Inst. 2014. PMID: 24273215 Review.

9

Response.

Ocana A, Vera-Badillo F, Templeton A, Tannock I, Amir E. Ocana A, et al. J Natl Cancer Inst. 2015 Aug 17;107(10):djv244. doi: 10.1093/jnci/djv244. Print 2015 Oct. J Natl Cancer Inst. 2015. PMID: 26283612 No abstract available.

10

Targeting the EGF/HER Ligand-Receptor System in Cancer.

Esparís-Ogando A, Montero JC, Arribas J, Ocaña A, Pandiella A. Esparís-Ogando A, et al. Among authors: ocana a. Curr Pharm Des. 2016;22(39):5887-5898. doi: 10.2174/1381612822666160715132233. Curr Pharm Des. 2016. PMID: 27426127 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

286 results

Search Page

Filters